TORONTO/MONTREAL, Nov 13 (Reuters) – Johnson & Johnson’s Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec’s public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows. The plan’s administrator stopped covering Remicade, J&J unit Janssen’s version of the drug infliximab, for some new patients in February 2017, in favor of cheap near-copies called biosimilars, mainly Pfizer Inc’s version of infliximab, called Inflectra. …read more
Source:: Yahoo Finance
